Edema
Drug research and approvals for edema: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 191 studies of edema are recruiting on ClinicalTrials.gov, Health Canada has authorized 25 drug trials for it since 2013, FDA has 0 approved and 9 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 191
- Trials authorized in Canada: 25
- FDA orphan approvals: 0
- EU medicines: 4
Recruiting Now
Newest start dates first, of 191 recruiting on ClinicalTrials.gov ↗- Using Bioimpedance Analysis to Monitor Fluid Status in ChildrenNCT07834710 · Not reported · St. Jude Children's Research Hospital · starts Nov 5, 2026
- Oral N-Acetylcysteine on Diabetic Macular EdemaNCT07917338 · Phase 2 · Khadija Ahmed Mhrose Glal · starts Oct 28, 2026
- Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1NCT07857733 · Phase 3 · Ambros Therapeutics, Inc. · starts Oct 13, 2026
- Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial DysfunctionNCT07729137 · Phase 2 · Emmecell · starts Oct 1, 2026
- "Effect of Endermologie-Assisted Physiotherapy on Edema, Pain, and Functional Recovery After Liposuction for Lower-Limb…NCT07618065 · Not applicable · Cairo University · starts Oct 1, 2026
- Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective StudyNCT07821450 · Not reported · Abdulkadir Küçük · starts Sep 25, 2026
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)NCT07705607 · Phase 3 · Merck Sharp & Dohme LLC · starts Sep 25, 2026
- A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).NCT07867080 · Phase 3 · 4D Molecular Therapeutics · starts Sep 18, 2026
- Dry Weight Reduction Intervention Via Extra UltrafiltrationNCT07637110 · Not applicable · University of Washington · starts Sep 10, 2026
- Extracorporeal Shock Wave Therapy in Lower Extremity LymphedemaNCT07626645 · Not applicable · Gazi University · starts Sep 1, 2026
Drug Pipeline
6 approved, 2 in phase 3, 3 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Spironolactone, Triamterene, Acetazolamide, Chlorothiazide, Hydrochlorothiazide, Witch hazel
- Collagenase clostridium histolyticum
- Phase 3 Collagen hydrolytic enzyme
- Albumin human
- Phase 3 Bilirubin sequestering agent
- Tacrolimus anhydrous
- Phase 2 FK506-binding protein 1A inhibitor
- Fexofenadine
- Phase 2 Histamine H1 receptor antagonist
- Gelatin
- Phase 2
- Furosemide
- Phase 1 Sodium-(potassium)-chloride cotransporter 2 inhibitor
- Corticorelin acetate
- Phase 1
How Its Trials Ended
827 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 227 whose ending is known, 48% met their primary endpoint, 5% missed it and 48% stopped early.
- Completed, result not reported35543%
- Status unknown12916%
- Ongoing11614%
- Met its primary endpoint10813%
- Stopped: other or unclear668%
- Stopped: enrollment or feasibility223%
- Missed its primary endpoint111%
- Stopped: lack of efficacy111%
- Stopped: sponsor or business decision61%
- Stopped: safety30%
Trials Authorized in Canada
The 10 newest of 25; search them all in Canada trials| Dec 21, 2022 | A phase III, multi¿center, randomized, double¿masked, sham¿controlled study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of…RO7200220 (IL-6 mab) | Roche | Ongoing |
| Dec 12, 2022 | Cuff leak test and airway obstruction in mechanically ventilated icu patients (cosmic): a vanguard pilot randomized controlled trialDexamethasone | St. Joseph'S Healthcare Hamilton | Closed |
| Nov 22, 2022 | Treat & extend versus fixed dosing with faricimab for management of diabetic macular edema: a pragmatic, multi-center, open-label, randomized, controlled trialFaricimab | Mcmaster University | Ongoing |
| Apr 1, 2022 | Evaluation of safety and efficacy of the ibe-814 intravitreal implant in patients with diabetic macular oedema and macular oedema due to retinal vein occlusion.IBE-814 | Ripple Therapeutics Corporation | Closed |
| Mar 3, 2022 | A phase II, multicenter, randomized, double masked, active comparator controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and…RO7200220 / ranibizumab (RO4893594 ) | Roche | Ongoing |
| Mar 2, 2022 | A phase II, multicenter, randomized, double masked, active comparator controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and…RO7200220 (IL-6 mab) / ranibizumab (RO4893594 ) | Roche | Ongoing |
| Jun 30, 2021 | A phase 2a, prospective, multicenter, randomized, double-masked, sham-controlled study to assess the safety, tolerability and evidence of activity of a single…UBX1325 | Unity Biotechnology | Closed |
| Nov 6, 2020 | An exploratory, prospective, multi-center, open-label, single-arm, interventional, phase IIb study to investigate aqueous humor and multimodal imaging…Faricimab (RO6867461) | Roche | Closed |
| Nov 4, 2020 | Ozurdex in suboptimal diabetic macular edemaDexamethasone | Dr Sohel Somani | Pending |
| Apr 28, 2020 | A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edemaHigh-dose aflibercept | Regeneron | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Mar 25, 2026 | (S)-N-(4-(2-(4-chlorophenyl)but-3-yn-2-yl)…Treatment of retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome | Drug Farm | Designated |
| Mar 4, 2025 | Tabirafusp alfaTreatment of uveitic macular edema (UME) | Kodiak Sciences Inc. | Designated |
| Aug 15, 2022 | VamikibartTreatment of uveitic macular edema | Genentech, Inc | Designated |
| Jan 12, 2017 | GlyburideTreatment of severe cerebral edema in patients with acute ischemic stroke | Remedy Pharmaceuticals, Inc. | Designated |
| Jan 16, 2013 | Synthetic peptide;…Treatment of high altitude pulmonary edema | Apeptico Forschung und Entwicklung GmbH | Designated |
| May 5, 2004 | IcatibantTreatment of burn patients hospitalized with burn-induced edema | Shire Human Genetic Therapies | Designated |
| Apr 6, 1998 | Corticotropin-releasing factor, humanTreatment of peritumoral brain edema. | Neurobiological Technologies, Inc. | Designated |
| Dec 22, 1993 | Neutrophil-endothelial interaction inhibitorTreatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension. | Cytel Corporation | Designated |
| Feb 22, 1990 | GlyceolTo decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy. | Chugai Pharmaceutical Co., Ltd. | Designated |
Medicines Authorised in the EU
Newest first| May 29, 2026 | BopediatFurosemide | Proveca Pharma Limited | EMA ↗ |
| Sep 15, 2023 | YesafiliAflibercept · biosimilar | Biosimilar Collaborations Ireland Limited | EMA ↗ |
| May 26, 2023 | QaialdoSpironolactone | Lipomed GmbH | EMA ↗ |
| Jul 26, 2010 | OzurdexDexamethasone | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA